Evidence map›Paper›PMID 41012548›Full record

ArticlePharmaceutics2025

Yanan Zhao, Ming Song, Yilizilan Dilixiati, Shanshan Cai, Reyilanmu Maisaidi, Patanmu Aili, Jinyao Li, Lili Han, Adila Aipire

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanan ZhaoXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Ming SongXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Yilizilan DilixiatiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Shanshan CaiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Reyilanmu MaisaidiDepartment of Gynecology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Patanmu AiliXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Jinyao LiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.ORCID 0000-0002-3295-6096
Lili HanDepartment of Gynecology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China.
Adila AipireXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.

Funding

the Key research and development program in Xinjiang Uygur Autonomous Region 2022B03018-5the Natural Science Foundation of Xinjiang Uygur Autonomous Region 2022D01C97Tianshan Talent Training Program 2023TSYCLJ0043
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antigen deliveryantitumorDC vaccineGUPS-AuNPsimmune enhancement

Identifiers

PMID41012548
PMCPMC12473970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.